Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
US-2017335010-A1 · Nov 23, 2017 · US
Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
US9969975B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9969975-B1 |
| Application number | US-201815865089-A |
| Country | US |
| Kind code | B1 |
| Filing date | Jan 8, 2018 |
| Priority date | Oct 5, 2015 |
| Publication date | May 15, 2018 |
| Grant date | May 15, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A genetically-modified human T cell comprising in its genome a modified human T cell receptor (TCR) alpha constant region gene, wherein said modified human TCR alpha constant region gene comprises from 5′ to 3′: (a) a 5′ region of a human TCR alpha constant region gene which is endogenous to said T cell; (b) an exogenous nucleic acid sequence encoding a chimeric antigen receptor; and (c) a 3′ region of said human TCR alpha constant region gene which is endogenous to said T cell; wherein said chimeric antigen receptor comprises a ligand-binding domain having specificity for an antigen present on a cancer cell, and wherein said genetically-modified human T cell expresses said chimeric antigen receptor and exhibits reduced cell-surface expression of the endogenous T cell receptor when compared to unmodified control cells. 2. The cell of claim 1 , wherein said exogenous nucleic acid sequence comprises a promoter sequence that drives expression of said chimeric antigen receptor. 3. The cell of claim 1 , wherein said chimeric antigen receptor comprises an intracellular cytoplasmic signaling domain. 4. The cell of claim 1 , wherein said chimeric antigen receptor comprises an intracellular co-stimulatory signaling domain. 5. The cell of claim 1 , wherein said chimeric antigen receptor comprises a signal peptide. 6. The cell of claim 1 , wherein said chimeric antigen receptor comprises a hinge domain. 7. The cell of claim 1 , wherein said chimeric antigen receptor comprises a transmembrane domain. 8. The cell of claim 1 , wherein said ligand-binding domain of said chimeric antigen receptor is specific for CD19. 9. The cell of claim 1 , wherein said exogenous nucleic acid sequence is inserted into said TCR alpha constant region gene which is endogenous to said T cell at a position within SEQ ID NO: 3.
Assignees
Inventors
Classifications
Immunoglobulin superfamily · CPC title
containing a localisation/targetting motif · CPC title
containing a signal sequence · CPC title
from tumour cells · CPC title
T-cell receptor (TcR)-CD3 complex · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9969975B1 cover?
- Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
- Who is the assignee on this patent?
- Prec Biosciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0636. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).